Coronary/Structural Heart

CorVista Health Announces AHA Presentation of Machine Learning to Detect Pulmonary Hypertension at Point-of-Care

WASHINGTON–(BUSINESS WIRE)– #ML–CorVista Health, Inc., a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the presentation of Machine Learning to Detect Pulmonary Hypertension data at AHA. “We are pleased to present this important data at this year’s AHA meeting.” said Don Crawford, President and CEO of CorVista Health. “Pulmonary hypertension is a challenging condition to diagnose, especially early in the disease progression. This pres

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

PALO ALTO, Calif.–(BUSINESS WIRE)–Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension. The Paradise system is intended as an adjunctive treatment […]

Xenter Unveils Groundbreaking Investigational Dual Sensor Wireless GuideWire for Minimally Invasive TAVR Procedures at TCT 2023

DRAPER, Utah–(BUSINESS WIRE)–Xenter, Inc. (Xenter.io) announced the recent unveiling of its groundbreaking dual sensor investigational guidewire for TAVR procedures at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference in San Francisco, CA. Xenter introduced the first-of-its-kind wireless guidewire designed for use during transcatheter aortic valve replacement (TAVR) procedures that aims to collect an extensive range of crucial real-time data points to serve as an aortic regu

Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023

BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the Company will present preclinical data on its Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor program at the American Heart Association’s (AHA) Scientific Sessions 2023. Cardurion is the first

MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting

Integrated polygenic risk score more accurately identified individuals at elevated risk for developing coronary artery disease, especially within borderline or intermediate clinical risk categories and for South Asian individuals MENLO PARK, Calif., Nov. 2, 2023 /PRNewswire/ — MyOme, Inc….